Literature DB >> 2890589

Haemodynamic dose-response actions of cicloprolol in left ventricular dysfunction due to ischaemic heart disease.

B Silke1, S P Verma, S K Sharma, W Baig, N C Jackson, G Reynolds, M A Frais, S H Taylor.   

Abstract

Cicloprolol is a cardioselective beta-1 partial agonist; its haemodynamic and radionuclide (nuclear stethoscope) effects were determined in 22 patients with impaired left ventricular function due to coronary artery disease. Following a 20 min stable control period, the effects of four doses of cicloprolol (0.025, 0.025, 0.05 and 0.1 mg/kg at 10 min intervals) were measured at rest 5-10 min after each intravenous injection. The effects of the cumulative 0.2 mg/kg dosage were assessed during supine bicycle exercise and compared with a control exercise period. At rest there were significant increases in systolic arterial without change in mean blood pressure. The heart rate and cardiac index were unchanged. There was a significant increase in left ventricular ejection fraction with a reduction in filling pressure and volume. Patients with resting heart rate below 75 beats/min and with ejection fraction greater than 35% showed the greatest improvement. During supine bicycle exercise, ejection fraction was increased compared to control (31 +/- 2 to 36 +/- 2; P less than 0.01), cardiac volume reduced and exercise tachycardia attenuated. These data suggest that cicloprolol may be of value where beta-blockade is considered in the presence of underlying left ventricular dysfunction due to ischaemic heart disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890589     DOI: 10.1016/0167-5273(87)90124-0

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Pharmacokinetics and safety of cicloprolol in uraemic patients.

Authors:  J P Fillastre; M Aparicio; C Porquet; C Dubruc; P Rosenzweig; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

Review 2.  Beta receptor antagonists in the treatment of heart failure.

Authors:  H Persson; L Erhardt
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

3.  Studies of the agonist and antagonist activity of cicloprolol in man.

Authors:  P M McCaffrey; M Burke; J G Riddell; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Combined invasive and noninvasive study of left ventricular systolic and diastolic function following acute administration of cicloprolol to subjects with normal cardiac function.

Authors:  L Bonandi; M Metra; L Niccoli; F Ettori; S Nodari; L Dei Cas; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1992-10       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.